Cargando…
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study
PURPOSE: Patients with recurrent glioblastoma (rGBM) have a poor prognosis. Epidermal growth factor receptor (EGFR) gene amplification is present in ~ 50% of glioblastomas (GBMs). Depatuxizumab mafodotin (depatux-m), formerly ABT-414, is an antibody–drug conjugate that preferentially binds cells wit...
Autores principales: | van den Bent, Martin, Gan, Hui K., Lassman, Andrew B., Kumthekar, Priya, Merrell, Ryan, Butowski, Nicholas, Lwin, Zarnie, Mikkelsen, Tom, Nabors, Louis B., Papadopoulos, Kyriakos P., Penas-Prado, Marta, Simes, John, Wheeler, Helen, Walbert, Tobias, Scott, Andrew M., Gomez, Erica, Lee, Ho-Jin, Roberts-Rapp, Lisa, Xiong, Hao, Bain, Earle, Ansell, Peter J., Holen, Kyle D., Maag, David, Reardon, David A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5686264/ https://www.ncbi.nlm.nih.gov/pubmed/29075855 http://dx.doi.org/10.1007/s00280-017-3451-1 |
Ejemplares similares
-
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial
por: Lassman, Andrew B, et al.
Publicado: (2019) -
Efficacy and safety results of depatuxizumab mafodotin (ABT‐414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor
por: Goss, Glenwood D., et al.
Publicado: (2018) -
A Phase 3b Study for Management of Ocular Side Effects in Patients with Epidermal Growth Factor Receptor-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin
por: Vize, Colin J., et al.
Publicado: (2023) -
Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial
por: Lassman, Andrew B, et al.
Publicado: (2022) -
Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial
por: Narita, Yoshitaka, et al.
Publicado: (2021)